Omega Fund Management, LLC Long-Term Concentrated

CIK: 0001637359 · Show all filings

Period: Q3 2020 (← Previous) (Next →)

Filing Date: Nov 16, 2020

Total Value ($000): $369,660 (100.0% shares, 0.0% debt)

Holdings (16)

REPL Replimune Group 33.1%

Value ($000) $122,395 Shares 5,344,971 Est. Cost $17.40 Unrealized +31.0%

— Morphic Holding 22.0%

Value ($000) $81,414 Shares 2,977,832 Est. Cost $19.82 Unrealized —

GOSS Gossamer Bio 11.1%

Value ($000) $41,209 Shares 3,320,608 Est. Cost $20.85 Unrealized -36.4%

IMUX Immunic 9.0%

Value ($000) $33,206 Shares 1,788,160 Est. Cost $13.89 Unrealized +17.9%

ARQT Arcutis Biothereapeutics 5.2%

Value ($000) $19,306 Shares 658,908 Est. Cost $26.87 Unrealized -0.6%

— Checkmate Pharmaceuticals 4.2%

Value ($000) $15,366 Shares 1,335,050 Est. Cost $11.51 Unrealized —

— Paratek Pharmaceuticals 3.8%

Value ($000) $14,068 Shares 2,600,410 Est. Cost $34.18 Unrealized —

— Alpine Immune Sciences 3.1%

Value ($000) $11,294 Shares 1,284,900 Est. Cost $8.79 Unrealized —

— ESSA Pharma 1.6%

Value ($000) $6,096 Shares 912,693 Est. Cost $3.14 Unrealized —

— Cidara Therapeutics 1.5%

Value ($000) $5,715 Shares 2,005,249 Est. Cost $5.64 Unrealized —

TRVI Trevi Therapeutics 1.5%

Value ($000) $5,545 Shares 1,375,907 Est. Cost $8.20 Unrealized -42.7%

— FibroGen 1.5%

Value ($000) $5,372 Shares 130,646 Est. Cost $27.34 Unrealized —

— Jounce Therapeutics 0.7%

Value ($000) $2,733 Shares 334,965 Est. Cost $21.99 Unrealized —

— ObsEva 0.7%

Value ($000) $2,478 Shares 999,364 Est. Cost $9.76 Unrealized —

— Prevail Therapeutics 0.5%

Value ($000) $1,909 Shares 187,538 Est. Cost $13.20 Unrealized —

— Pieris Pharmaceuticals 0.4%

Value ($000) $1,554 Shares 750,741 Est. Cost $1.83 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
REPL	Replimune Group	5,344,971	$122,395	33.1%	$17.40	+31.0%	Common Stock	76029N106
—	Morphic Holding	2,977,832	$81,414	22.0%	$19.82	—	Common Stock	61775R105
GOSS	Gossamer Bio	3,320,608	$41,209	11.1%	$20.85	-36.4%	Common Stock	38341P102
IMUX	Immunic	1,788,160	$33,206	9.0%	$13.89	+17.9%	Common Stock	4525EP101
ARQT	Arcutis Biothereapeutics	658,908	$19,306	5.2%	$26.87	-0.6%	Common Stock	03969K108
—	Checkmate Pharmaceuticals	1,335,050	$15,366	4.2%	$11.51	—	Common Stock	162818108
—	Paratek Pharmaceuticals	2,600,410	$14,068	3.8%	$34.18	—	Common Stock	699374302
—	Alpine Immune Sciences	1,284,900	$11,294	3.1%	$8.79	—	Common Stock	02083G100
—	ESSA Pharma	912,693	$6,096	1.6%	$3.14	—	Common Stock	29668H708
—	Cidara Therapeutics	2,005,249	$5,715	1.5%	$5.64	—	Common Stock	171757107
TRVI	Trevi Therapeutics	1,375,907	$5,545	1.5%	$8.20	-42.7%	Common Stock	89532M101
—	FibroGen	130,646	$5,372	1.5%	$27.34	—	Common Stock	31572Q808
—	Jounce Therapeutics	334,965	$2,733	0.7%	$21.99	—	Common Stock	481116101
—	ObsEva	999,364	$2,478	0.7%	$9.76	—	Common Stock	H5861P103
—	Prevail Therapeutics	187,538	$1,909	0.5%	$13.20	—	Common Stock	74140Y101
—	Pieris Pharmaceuticals	750,741	$1,554	0.4%	$1.83	—	Common Stock	720795103